CompletedPHASE1, PHASE2NCT01710644

Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Studying Cystic fibrosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Nordmark Arzneimittel GmbH & Co. KG
Principal Investigator
Kristin Forssmann, MD
Nordmark Arzneimittel GmbH & Co. KG
Intervention
Burlulipase(drug)
Enrollment
35 enrolled
Eligibility
12 years · All sexes
Timeline
20132014

Study locations (9)

Collaborators

Parexel

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01710644 on ClinicalTrials.gov

Other trials for Cystic fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Cystic fibrosis

← Back to all trials